ElectroCore's GammaCore Therapy Will Continue To Be Listed In The U.K's National Health Service Supply Chain Catalogue For Additional Two Years Till March 17, 2026. The Listing Commenced On June 4, 2019, Was Scheduled To Terminate On March 18, 2024
Portfolio Pulse from Benzinga Newsdesk
ElectroCore's GammaCore Therapy will continue to be listed in the U.K's National Health Service Supply Chain Catalogue for an additional two years until March 17, 2026. The listing, which commenced on June 4, 2019, was initially scheduled to terminate on March 18, 2024.
October 17, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The extension of ElectroCore's GammaCore Therapy listing in the U.K's NHS Supply Chain Catalogue could potentially increase the company's market exposure and sales in the U.K.
The extension of the listing of ElectroCore's GammaCore Therapy in the U.K's NHS Supply Chain Catalogue means that the product will continue to be available for purchase by the NHS for an additional two years. This could potentially increase the company's market exposure and sales in the U.K, which could have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100